Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Upgrades FinVolution Gr to Buy

UBS analyst Alex Ye upgrades FinVolution Gr (NYSE:FINV) from Neutral to Buy.
byBenzinga Newsdesk
February 1, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

UBS analyst Alex Ye upgrades FinVolution Gr (NYSE:FINV) from Neutral to Buy.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Coherus Presents Phase 2 Clinical Data On Casdozokitug, A First-in-Class IL-27-Targeted Antibody, At The 2024 ASCO GI Cancers Symposium; The Primary Endpoint Of The Lead-in Portion Of The Study Was Safety And Tolerability

By Benzinga Newsdesk
January 18, 5:16 PM
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –– Data support casdozo as a promising novel immuno-oncology agent with

CHRS